<DOC>
	<DOCNO>NCT00460148</DOCNO>
	<brief_summary>This study PD patient design assess affect food absorption , distribution , metabolism excretion ropinirole ( dose patient fasted state patient follow high-fat breakfast ) , assess difference absorption , distribution , metabolism excretion ropinirole patient give three 4mg ropinirole tablet versus one 12mg tablet .</brief_summary>
	<brief_title>Parkinson 's Disease Patient Study On Absorption , Distribution , Metabolism And Excretion Of Ropinirole</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Male female patient age 30 85 year age Body mass index 18 32 kg/m2 , body weight least 50 kg . Diagnosis idiopathic Parkinson 's disease Patients must provide write informed consent prior perform study procedure QTc interval &lt; 450ms ( QTc &lt; 480ms patient Bundle Branch Block ) . Patients abnormality physical examination . Patients medical condition could present safety concern . Patients clinically significant abnormal laboratory value , ECG , physical examination find Positive result Hepatitis B surface antigen , Hepatitis C antibody Human Immunodeficiency Virus ( HIV ) antibody Positive alcohol test result / urine test undeclared drug Recent history moderate severe dizziness , syncope , orthostatic hypotension Significant sleep disorder Epworth Sleep Score ( Appendix 5 ) &gt; 9 Patients lying/sitting diastolic blood pressure =110mmHg =50mmHg systolic blood pressure =180mmHg =90mmHg History dopaminergic treatment ( ropinirole IR Ldopa ) within 2 week prior first dose . Withdrawal , introduction , change dose hormone replacement therapy and/or drug know substantially inhibit CYP1A2 induce CYP1A2 Patients smoke &gt; 20 cigarette per day maintain constant smoking habit duration study . Blood donation significant blood loss le 90 day Day 1 current study . Definite suspect personal history , family history , adverse reaction hypersensitivity ropinirole drug similar chemical structure . Use investigational drug ( exception ropinirole PR/CR ) within 30 day 5 half life ( whichever longer ) start dose study medication . Patients receive overthecounter ( OTC ) medicine within 48 h first dose study drug . Recent history , suspicion , drug dependence abuse alcohol Significant concern , likelihood , patient drop study prematurely , require new prohibit concomitant medication study period , compliant study procedure . Women pregnant breastfeeding . Female patient currently either : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal female surgically sterilize ( via document hysterectomy bilateral tubal ligation ) . ( For purpose study , postmenopausal define one year without menses ) OR 2. childbearing potential , negative urine/serum pregnancy test Screening Visit ( prior investigational product administration ) , agree use acceptable contraception one month prior study Day 1 one month completion study ( ie . one month followup visit ) . All hormonal birth control must administer least one monthly cycle prior Screening Visit . GSK acceptable contraception method , use consistently accordance product label instruction physician , follow : complete abstinence sterilization patient 's male partner prior female patient 's entry study oral contraceptive ( either combine progestogen ) intrauterine device document failure rate le 1 % per year systemic contraception ( eg . norplant system ) double barrier method comprise spermicide either condom diaphragm Patients prior current major psychosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ropinirole PR/CR ,</keyword>
	<keyword>pharmacokinetic ,</keyword>
	<keyword>formulation ,</keyword>
	<keyword>food effect ,</keyword>
	<keyword>SK &amp; F101468 ,</keyword>
	<keyword>PD</keyword>
</DOC>